Literature DB >> 21755942

Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824).

Joseph Cherian1, Inhee Choi, Amit Nayyar, Ujjini H Manjunatha, Tathagata Mukherjee, Yong Sok Lee, Helena I Boshoff, Ramandeep Singh, Young Hwan Ha, Michael Goodwin, Suresh B Lakshminarayana, Pornwaratt Niyomrattanakit, Jan Jiricek, Sindhu Ravindran, Thomas Dick, Thomas H Keller, Veronique Dartois, Clifton E Barry.   

Abstract

The (S)-2-nitro-6-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine named PA-824 (1) has demonstrated antitubercular activity in vitro and in animal models and is currently in clinical trials. We synthesized derivatives at three positions of the 4-(trifluoromethoxy)benzylamino tail, and these were tested for whole-cell activity against both replicating and nonreplicating Mycobacterium tuberculosis (Mtb). In addition, we determined their kinetic parameters as substrates of the deazaflavin-dependent nitroreductase (Ddn) from Mtb that reductively activates these pro-drugs. These studies yielded multiple compounds with 40 nM aerobic whole cell activity and 1.6 μM anaerobic whole cell activity: 10-fold improvements over both characteristics from the parent molecule. Some of these compounds exhibited enhanced solubility with acceptable stability to microsomal and in vivo metabolism. Analysis of the conformational preferences of these analogues using quantum chemistry suggests a preference for a pseudoequatorial orientation of the linker and lipophilic tail.
© 2011 American Chemical Society

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21755942      PMCID: PMC3158291          DOI: 10.1021/jm1010644

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  19 in total

1.  The use of in vitro metabolic stability for rapid selection of compounds in early discovery based on their expected hepatic extraction ratios.

Authors:  Yan Yi Lau; Gopal Krishna; Nathan P Yumibe; Diane E Grotz; Elpida Sapidou; Laura Norton; Inhou Chu; Cliff Chen; A D Soares; Chin-Chung Lin
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

2.  Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.

Authors:  Hirofumi Sasaki; Yoshikazu Haraguchi; Motohiro Itotani; Hideaki Kuroda; Hiroyuki Hashizume; Tatsuo Tomishige; Masanori Kawasaki; Makoto Matsumoto; Makoto Komatsu; Hidetsugu Tsubouchi
Journal:  J Med Chem       Date:  2006-12-28       Impact factor: 7.446

3.  High-accuracy quantum mechanical studies of pi-pi interactions in benzene dimers.

Authors:  Mutasem Omar Sinnokrot; C David Sherrill
Journal:  J Phys Chem A       Date:  2006-09-21       Impact factor: 2.781

4.  Do special noncovalent pi-pi stacking interactions really exist?

Authors:  Stefan Grimme
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

5.  Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates.

Authors:  Laura E Via; P Ling Lin; Sonja M Ray; Jose Carrillo; Shannon Sedberry Allen; Seok Yong Eum; Kimberly Taylor; Edwin Klein; Ujjini Manjunatha; Jacqueline Gonzales; Eun Gae Lee; Seung Kyu Park; James A Raleigh; Sang Nae Cho; David N McMurray; JoAnne L Flynn; Clifton E Barry
Journal:  Infect Immun       Date:  2008-03-17       Impact factor: 3.441

6.  Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824.

Authors:  Xiaojin Li; Ujjini H Manjunatha; Michael B Goodwin; John E Knox; Christopher A Lipinski; Thomas H Keller; Clifton E Barry; Cynthia S Dowd
Journal:  Bioorg Med Chem Lett       Date:  2008-03-07       Impact factor: 2.823

7.  Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).

Authors:  Brian D Palmer; Andrew M Thompson; Hamish S Sutherland; Adrian Blaser; Iveta Kmentova; Scott G Franzblau; Baojie Wan; Yuehong Wang; Zhenkun Ma; William A Denny
Journal:  J Med Chem       Date:  2010-01-14       Impact factor: 7.446

8.  Structure-activity relationships of antitubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activity relationships.

Authors:  Pilho Kim; Sunhee Kang; Helena I Boshoff; Jan Jiricek; Margaret Collins; Ramandeep Singh; Ujjini H Manjunatha; Pornwaratt Niyomrattanakit; Liang Zhang; Michael Goodwin; Thomas Dick; Thomas H Keller; Cynthia S Dowd; Clifton E Barry
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

9.  OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.

Authors:  Makoto Matsumoto; Hiroyuki Hashizume; Tatsuo Tomishige; Masanori Kawasaki; Hidetsugu Tsubouchi; Hirofumi Sasaki; Yoshihiko Shimokawa; Makoto Komatsu
Journal:  PLoS Med       Date:  2006-11       Impact factor: 11.069

10.  PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release.

Authors:  Ramandeep Singh; Ujjini Manjunatha; Helena I M Boshoff; Young Hwan Ha; Pornwaratt Niyomrattanakit; Richard Ledwidge; Cynthia S Dowd; Ill Young Lee; Pilho Kim; Liang Zhang; Sunhee Kang; Thomas H Keller; Jan Jiricek; Clifton E Barry
Journal:  Science       Date:  2008-11-28       Impact factor: 63.714

View more
  8 in total

1.  Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids.

Authors:  David F Bruhn; Michael S Scherman; Aman P Singh; Lei Yang; Jiuyu Liu; Anne J Lenaerts; Richard E Lee
Journal:  Bioorg Med Chem Lett       Date:  2015-12-07       Impact factor: 2.823

2.  Copper-Catalyzed Chan-Lam Cyclopropylation of Phenols and Azaheterocycles.

Authors:  Joseph Derosa; Miriam L O'Duill; Matthew Holcomb; Mark N Boulous; Ryan L Patman; Fen Wang; Michelle Tran-Dubé; Indrawan McAlpine; Keary M Engle
Journal:  J Org Chem       Date:  2018-03-13       Impact factor: 4.354

3.  Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.

Authors:  Sidharth Chopra; Gary A Koolpe; Arlyn A Tambo-Ong; Karen N Matsuyama; Kenneth J Ryan; Tran B Tran; Rupa S Doppalapudi; Edward S Riccio; Lalitha V Iyer; Carol E Green; Baojie Wan; Scott G Franzblau; Peter B Madrid
Journal:  J Med Chem       Date:  2012-06-25       Impact factor: 7.446

Review 4.  Functionalized Nitroimidazole Scaffold Construction and Their Pharmaceutical Applications: A 1950-2021 Comprehensive Overview.

Authors:  Ria Gupta; Sumit Sharma; Rohit Singh; Ram A Vishwakarma; Serge Mignani; Parvinder Pal Singh
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-30

5.  Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis.

Authors:  Suresh B Lakshminarayana; Helena I M Boshoff; Joseph Cherian; Sindhu Ravindran; Anne Goh; Jan Jiricek; Mahesh Nanjundappa; Amit Nayyar; Meera Gurumurthy; Ramandeep Singh; Thomas Dick; Francesca Blasco; Clifton E Barry; Paul C Ho; Ujjini H Manjunatha
Journal:  PLoS One       Date:  2014-08-20       Impact factor: 3.240

6.  Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of Pretomanid.

Authors:  Andrew M Thompson; Muriel Bonnet; Ho H Lee; Scott G Franzblau; Baojie Wan; George S Wong; Christopher B Cooper; William A Denny
Journal:  ACS Med Chem Lett       Date:  2017-11-13       Impact factor: 4.345

Review 7.  Pretomanid for tuberculosis treatment: an update for clinical purposes.

Authors:  Sara Occhineri; Tommaso Matucci; Laura Rindi; Giusy Tiseo; Marco Falcone; Niccolò Riccardi; Giorgio Besozzi
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-09-09

Review 8.  Recent Progress in the Discovery and Development of 2-Nitroimidazooxazines and 6-Nitroimidazooxazoles to Treat Tuberculosis and Neglected Tropical Diseases.

Authors:  Hollis D Showalter
Journal:  Molecules       Date:  2020-09-10       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.